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Abstract
Background—Hyperhomocysteinemia may be a modifiable risk factor for the prevention of
arteriosclerotic outcomes in chronic kidney disease (CKD). Few clinical trials of homocysteine
lowering have been conducted in persons with CKD prior to reaching end-stage renal disease. Kidney
transplant recipients are considered individuals with CKD.
Objectives—To describe the baseline characteristics of renal transplant recipients (RTRs) enrolled
in a clinical trial of homocyteine lowering with a standard multivitamin containing high doses of
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folic acid, vitamins B6 and B12 aimed at reducing arteriosclerotic outcomes. Factors considered were
level of kidney function, total homocysteine (tHcy) concentrations, and the prevalence of diabetes
and previous cardiovascular disease (CVD).
Study Design—Cross sectional survey within a randomized controlled trial (RCT) cohort.
Setting and Participants—Participants were recruited from kidney transplant clinics in the U.S.,
Canada, and Brazil. Eligible participants had elevated levels of homocysteine (≥12.0 μmol/L in men
and ≥11.0 μmol/L in women) and kidney function measured by Cockroft Gault estimated creatinine
clearance of 30 mL/min or greater.
Results—Among 4,110 randomized participants 38.9% had diabetes, and 19.5% had previous
CVD. Mean (± standard deviation) tHcy concentrations were 17.1 ± 6.3 μmol/L, while the mean (±
standard deviation) creatinine clearance was 66.4 ± 23.2 mL/min. Approximately 90% of the trial
cohort had an estimated glomerular filtration rate (eGFR) consistent with stage 2-3 CKD (i.e., eGFR
30-89 mL/min).
Limitations—Analysis is based on cross-sectional data from a RCT, self-report of co-morbid
illnesses, and level of kidney function was estimated.
Conclusions—A large population of stable RTRs who are at high risk for the development of CVD
(both de novo and recurrent) has been recruited into FAVORIT and are likely to experience a
sufficient number of events to address the primary hypothesis of the trial.
Index Words
chronic kidney disease; renal transplantation; hyperhomocysteinemia; creatinine clearance;
estimated GFR; arteriosclerosis; diabetes
Introduction
Chronic kidney disease (CKD) increases substantially the risk of cardiovascular disease
(CVD). The increase in risk can be attributed, in part, to a higher prevalence of established
arteriosclerotic risk factors, including older age, hypertension, diabetes, dyslipidemia, and
physical inactivity. However, these established risk factors do not account adequately for the
excess burden of CVD observed in the CKD population. 1 This observation has led to the
search for non-traditional risk factors that may also contribute to this excess CVD risk. 2 One
non-traditional risk factor, hyperhomocysteinemia or elevated concentrations of homocysteine,
a sulfur-containing amino acid by-product of methionine metabolism, has received
considerable attention over the past decade.
A number of prospective observational studies of persons with CKD prior to kidney failure,
which have been conducted throughout the world, have revealed a linear trend for increased
CVD risk, i.e., per μmol/L increase or across quantiles of total homocysteine (tHcy). As
expected, the greatest relative risk was confined to persons with higher levels of tHcy. 3, 4
Whether mild to moderate hyperhomocysteinemia is a risk factor for arteriosclerotic outcomes
in these populations or is only a surrogate for the apparent relationship between kidney function
and clinical CVD has not yet been resolved. Although a substantial number of randomized
controlled clinical trials of tHcy-lowering treatment have been undertaken in different at-risk
populations to evaluate efficacy for reducing CVD events, 5-13 including persons with CKD,
14 none have demonstrated a significant reduction in CVD risk.
The renal transplant patient population remains a suitable group to enroll in clinical trials to
test the “homocysteine-lowering hypothesis” since they have a high rate of both incident and
recurrent cardiovascular disease, 2 and continue to display an excess prevalence of
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hyperhomocysteinemia despite the fortification of cereal grain flour with folic acid. 3
Importantly, these patients are not routinely treated with supplemental folic acid, and are able
to “normalize” their tHcy levels with combined folic acid, vitamin B12, and vitamin B6
treatment. 15, 16 In contrast, hyperhomocysteinemia in end-stage renal disease (ESRD)
patients persists with such vitamin therapy,17 albeit at slightly lower tHcy levels. Furthermore,
at the 2004 Kidney Disease: Improving Global Outcomes (KDIGO) International
Controversies Conference on Definition and Classification of Chronic Kidney Disease in
Adults, the expert consensus was to “consider all kidney transplant recipients to have CKD,
irrespective of GFR level or presence or absence of markers of kidney damage.” 18 Although
there is great heterogeneity among causes of CKD, many of the complications of CKD in renal
transplant recipients are similar to those experienced by persons with CDK of their native
kidneys. 19 These observations led to the design and conduct of a randomized clinical trial of
homocysteine lowering in renal transplant recipients, the Folic Acid for Vascular Outcome
Reduction in Transplantation (FAVORIT) trial. 20
The primary objective of the FAVORIT trial is to determine whether lowering total
homocysteine levels in clinically stable renal transplant recipients with a multivitamin
containing high doses of folic acid (5.0 mg), vitamin B6 (pyridoxine, 50 mg) and vitamin B12
(cyanocobalamin, 1.0 mg) will reduce their risk of CVD compared to treatment with a “low
dose” multivitamin devoid of folic acid and with estimated average requirement (EAR)
amounts of vitamins B6 (1.4 mg) and B12 (2.0 μg). We describe the major demographic and
clinical characteristics at baseline for participants enrolled into the trial.
Methods
Details of the FAVORIT study design have been published previously. 20 Briefly, the trial is
being conducted at 30 clinical sites in the United States (27 sites), Canada (2 sites) and Brazil
(1 site), with support from an Operations Center, Data Coordinating Center, and Central
Laboratory. Study enrollment began in August 2002 and was completed in January 2007;
planned follow-up is through July 2011. The primary outcome is a combination of both clinical
events and invasive procedures for cardiovascular, peripheral vascular or renovascular disease.
A sample size of 4,000 with five years of follow-up is estimated to provide 87% power to detect
a 20% treatment effect. Institutional review board approval is maintained by all sites.
Study participants
Kidney transplant recipients were eligible for the study if they were aged 35 to 75 years, had
clinically stable kidney function and elevated tHcy levels. Stable kidney function was
ascertained by medical chart review to establish that the patient's current graft had been
functioning for at least six months post-transplantation and there was no documented clinical
indication of renal function deterioration. All enrolled participants had a Cockcroft-Gault
estimated creatinine clearance (Ccr) 21 of 30 mL/min or greater and elevated tHcy (≥12.0
μmol/L for men or ≥11.0 μmol/L for women) based on central laboratory analysis of screening
specimens. For women recruited after July 2005, the Ccr eligibility criteria was reduced to 25
mL/min or greater in acknowledgment of the lower Ccr distribution routinely observed in
women relative to the distribution in men. Individuals with chronic illness limiting life
expectancy less than 2 years were excluded, as were those with CVD risk modified because
of recent CVD-related events or procedures. Written informed consent was obtained from all
study participants.
Screening and baseline data
The screening visit began with the informed consent process for screening, baseline, and
follow-up contacts. Eligibility criteria were verified and fasting or non-fasting blood specimens
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(serum, plasma, buffy coat, and red blood cells) were collected for central analysis of creatinine
and total homocysteine, and for specimen banking. Based on the central laboratory
determinations, participants meeting laboratory eligibility values for Ccr and tHcy were
scheduled for the baseline (randomization) visit.
The study protocol allowed up to 120 days to elapse between screening and randomization.
Therefore, eligibility criteria were confirmed just prior to randomization. Participants meeting
all study criteria were equally randomly allocated to one of two treatment groups. Data on
regular medication use during the past month, blood pressure, height, weight, and medical
history were collected. Of note, history of diabetes includes any history, pre- or post-transplant,
including diabetes that may have resolved through pancreas transplant. Assessment of diabetes
history is a combination of data recorded in available medical records and self-reported medical
history. Race and ethnicity were defined in accordance with the National Institutes of Health
Policy on Reporting Race and Ethnicity Data. 22 The term ‘African American’ includes African
descendents in Brazil. Blood specimens were obtained to assess tHcy, folate, pyridoxal-5′-
phosphate (PLP), total cholesterol, triglycerides, high-density lipoprotein, low-density
lipoprotein, creatinine and glucose, and for specimen banking. Midstream clean catch urine
specimens were also collected for storage.
In spring 2005, the study protocol was modified to incorporate a mechanism to reduce the
participant burden of needing to make a special visit to complete the baseline examination.
Essentially, the screening visit was expanded to include all of the baseline data collection except
for final verification of eligibility and randomization; these could be completed through a
telephone contact up to 120 days following screening with baseline data collection.
Laboratory methods for major analytes
Total homocysteine was measured by an HPLC method based on the principles described by
Araki and Sako. 23 Serum creatinine was determined by a kinetic adaptation of the Jaffe
reaction 24 on a clinical chemistry analyzer, (Cobas Mira Analyzer, Roche Diagnostic Systems,
Inc., Indianapolis, IN), according to Larsen 25 and as modified by Roche Diagnostic Systems,
Inc. Serum total cholesterol, direct LDL-cholesterol, direct HDL-cholesterol, and triglyceride
were measured on a clinical chemistry automated analyzer, Olympus AU400,(Olympus
America Inc., 2 Corporate Center Drive, Melville, NY, 11747-3157), using Olympus America,
Inc. enzymatic reagents and calibrators, and according to protocol as specified in Olympus
AU400 standard operating procedure manual. When serum triglycerides were 400 mg/dL or
less, LDL-cholesterol was estimated using the Friedewald formula; 26 if serum triglycerides
were greater than 400 mg/dL, direct LDL-cholesterol was measured as indicated above.
Statistical analyses
All analyses except the power calculations in Table 1 were computed using SAS® version
9.1.27 P-values for comparisons by country and history of diabetes were based on chi-squared
test for categorical variables when all cell counts were 10 or greater. Otherwise, Fisher's Exact
Test was used. The analysis of variance f-test was used to test for a difference in means for
continuous variables. Estimated glomerular filtration rate (eGFR) was computed using the
Modification of Diet in Renal Disease Study (MDRD) equation based on serum creatinine
assays before calibration to isotope dilution mass spectrometry. 28
The post-hoc power estimates provided in Table 1 were calculated based on data taken from
published papers and abstracts. Power was computed using the observed event rate in the
control group and the attained sample sizes for each study. For the studies reported only in
abstract form 5, 6 in which sample sizes by treatment group were not reported, the sample size
in each treatment group was assumed to be one half of the total sample size. The power was
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computed for 10%, 15%, and 20% reduction in events for the treated group using a 5% (two-
sided) significance level in STATA version 7.
Results
A total of 7,273 renal transplant recipients met pre-screening criteria and had creatinine and
tHcy centrally assessed. As depicted in Figure 1, 4,753 (65%) of the screenees met the trial's
eligibility criteria for Ccr and tHcy level and among those 4,110 (86%) were randomized.
Although the study did not systematically collect reasons lab-eligible individuals were
otherwise ineligible or not randomized, frequently-cited responses included patients wanting
to take their own vitamins (usually to insure that folic acid was included), time or transportation
issues, and not wanting the additional commitment.
Major clinical and demographic characteristics of the randomized study participants assessed
at baseline are presented in Table 2. The 3,000 participants recruited in the United States were
similar in sex and donor type distributions but include a smaller proportion of individuals with
Hispanic ethnicity than kidney transplant recipients documented in the Organ Procurement and
Transplantation Network (Based on OPTN data as of January 18, 2008 from
http://www.optn.org/latestData/rptData.asp) for kidney transplants completed from 1988
through 2007 (60.0% male, 34.5% living donor, 11.5% Hispanic). Traditional CVD risk factors
varied by country with participants in the United States having a higher mean BMI (30 kg/
m2) and a larger proportion with a history of diabetes (43%) than participants in Brazil (27 kg/
m2 and 27%, respectively) and Canada (28 kg/m2 and 30%, respectively). Total cholesterol
level and systolic blood pressure were highest in Brazil (192 mg/dL and 145 mm Hg) and
lowest in Canada (178 mg/dL and 133 mm Hg). A smaller proportion of participants in Canada
(4%) were African American than in the United States (19%) or Brazil (21%). The mean tHcy
among all study participants at screening was 17.1 μmol/L and the prevalence of diabetes was
substantial (39%).
Consistent with their increased risk for the development of clinical arteriosclerosis, participants
with diabetes had more than double the prevalence of baseline CVD (29% vs. 13%), compared
to participants without diabetes. Moreover, the higher prevalence of risk factors for CVD in
participants with diabetes (slightly older, heavier, and higher systolic blood pressure than
persons without diabetes) suggests that incident cardiovascular disease will be elevated in this
group as well.
The distribution of estimated glomerular filtration rate based on the MDRD formula (eGFR)
at screening is provided in Table 3. Approximately 90% of the participants meet criteria for
stage 2-3 CKD (i.e., eGFR 30-89 mL/min).
Discussion
Cardiovascular disease remains the most common cause of morbidity and mortality in persons
with CKD. This increased risk along with the high prevalence of hyperhomocysteinemia, the
expected infrequency of treatment with supplemental folic acid, and the previously-
demonstrated ability to “normalize” tHcy levels in renal transplant recipients with combined
folic acid, vitamin B12 and vitamin B6 treatment makes kidney transplant recipients an
especially suitable population in which to test the effects of lowering homocysteine.
In order to test this hypothesis we recruited a large sample of stable kidney transplant recipients
who are at high risk of CVD. Most of the participants had either Stage 2 or 3 CKD based on
the MDRD Study formula. Moreover nearly forty percent had a diagnosis of diabetes, another
important risk factor for CVD, exceeding the estimate used in the original power calculation
(35%). As expected, a history of cardiovascular disease was more prevalent among the
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FAVORIT participants with diabetes than among those without diabetes (29% and 13%,
respectively). Thus the trial appears to be well poised to accrue a sufficient number of events
to address the primary hypothesis of whether homocysteine lowering in stable kidney transplant
recipients will significantly reduce arteriosclerotic cardiovascular disease. We are aware of the
results of nine tHcy-lowering clinical trials evaluating the potential reduction of cardiovascular
disease outcomes among various patient populations 5-13 and none have shown a beneficial
effect. However, each of these trials had limitations including failure to normalize tHcy levels,
8, 12, 13 the impact of folic acid fortification in folate “sensitive” non-CKD populations 5, 9,
11 or medication drop-ins who used up to 1 mg/day of folic acid 8 which may have reduced
study power.
One recently reported trial of homocysteine lowering in approximately 2,000 ESRD or stage
4 CKD patients, the Homocysteinemia in Kidney and End Stage Renal Disease (HOST) study,
reported that even a very high dose B-vitamin regimen for tHcy-lowering (40 mg/day folic
acid, 100 mg/day B6, and 2 mg/day B12) failed to reduce crude all-cause mortality during a
median of 3.2 years of follow-up. However, there was a trend for fewer myocardial infarctions
in the actively treated group compared to placebo. 8 In comparison, a subgroup analysis of
participants with CKD (GFR <60 ml/min) in the Heart Outcomes Prevention Evaluation 2
(HOPE-2) Study failed to show a beneficial effect of homocysteine lowering on cardiovascular
risk. 14
While the limited or lack of statistical power to detect CVD event rate changes of 20% in the
preliminary CKD patient trials, and even the larger HOST trial are clear (see Table 1), we
investigated whether the considerably larger non-CKD patient trial cohorts might also have
been inadequately powered based on their now reported control event rates. Only two 5, 9 of
the five 5-7, 9, 11 large trials completed in predominantly non-renal populations, HOPE-2 9
and Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS), 5 remained well-
powered (i.e., >=85%) to detect a 20% reduction in CVD events with active treatment, based
on the actual control group event rate. None of the trials are well-powered to detect a 10% or
15% reduction in CVD events. Furthermore, the mean tHcy concentration at baseline in
HOPE-2 was only 12.1 μmol/L, and was reduced by just 2.4 μmol/L with active treatment. 9
Comparable data from WAFACS reveal an initial level of 12.2 μmol/L, which was only reduced
by 2.2 μmol/L with active treatment. 5 In contrast, the Norwegian Vitamin trial (NORVIT)
participants had slightly higher baseline tHcy concentrations (13.1 μmol/L), and achieved a
greater absolute reduction (3.5 μmol/L), but when the actual control group event rate was
considered, the study lacked adequate statistical power to detect a 20% reduction in CVD event
rates. 7 The Cambridge Heart Antioxidant Study-2 (CHAOS-2), 6 and to a lesser extent the
Vitamin Intervention for Stroke Prevention trial (VISP),11 may have also suffered from the
combined effects of these limitations. In contrast, at screening, FAVORIT participants have a
mean tHcy level of 17.1 μmol/L in comparison to a range of baseline levels of 11.2-13.4 μmol/
L in these recently completed trials of patients without CKD. 5-7, 9, 11 We have previously
shown that 15-17 subsequent to chronic exposure to cereal grain flour products fortified with
folic acid, long-term kidney transplant recipients with mild hyperhomocysteinemia who were
similar to participants enrolled in FAVORIT, still experienced a nearly one-third (5.0-5.5
μmol/L) decrease during treatment with a folic acid, B12, and B6 regimen, and 50% of these
participants maintained their tHcy concentrations below 12 μmol/L. A similar reduction in
tHcy of 5-6 μmol/L is expected among the FAVORIT participants receiving the high dose
multivitamin. Thus, we anticipate that both the higher observed tHcy levels and expected
greater impact of tHcy-lowering vitamin therapy may enhance the likelihood of the FAVORIT
study showing a reduction of CVD risk compared to previous studies.
The FAVORIT trial has several potential limitations. As we have shown there are important
differences in several baseline CVD risk factors by country that could impact the observed
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event rate. However, these risk factor differences are not in the same direction. For example,
among participants in Brazil, mean BMI is lower whereas mean blood pressure is higher than
among participants in the U.S. Additionally, the within-country sample sizes are large and this
heterogeneity may increase the generalizability of the findings. Many important, albeit tertiary,
research questions will be addressed through analyses stratified by country or within the U.S.
subgroup. Another limitation of the baseline data is that history of disease was taken from
patient report and medical records without verification or classification using standardized
definitions as is being done prospectively with the myocardial infarction, stroke, resuscitated
sudden death, and cardiovascular death components of the FAVORIT primary endpoint. While
this is a limitation for cross-sectional baseline analyses, it will not affect the validity of the
primary trial objective. We also acknowledge that renal function is estimated instead of
measured GFR. However data are provided based on two well-established prediction equations
21, 28 for comparison with other scientific literature and clinical practice. However, these
equations have not been uniformly validated in kidney transplant recipients with stable renal
function. Finally, caution should be exercised if generalizing CKD among RTRs to CKD
among other patient groups.
FAVORIT has a number of strengths. The sample size of 4,110 chronic stable renal transplant
recipients is large. The planned period of follow-up (4.5 to 9 years) is long. This duration of
follow-up may detect a lag in treatment effect, a focus not considered in most previous clinical
trials. Screening data confirm that baseline tHcy levels are higher than in trials conducted
among non-CKD populations. Finally, with the projected FAVORIT event rate for CVD among
the control group, the trial appears to be adequately powered to discern even a moderate 20%
reduction in events (if achieved) with active tHcy-lowering treatment. Since FAVORIT
includes participants with predominantly stage 2 and stage 3 CKD the findings will provide
important information on the clinical benefit of tHcy-lowering with B-vitamin therapy among
this group and may indicate a low-cost intervention for the general CKD population.
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Figure 1. Screening and Enrollment Profile
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Table 2
Distribution of estimated glomerular filtration rate and CKD stage at
screening
United States Brazil Canada Overall
eGFR (ml/min)
 N 3000 612 498 4110
 Mean ± SD 50 ± 16.5 53 ± 16.5 50 ± 15.9 51 ± 16.5
 Range 16.1 - 152.7 17.5 - 116.9 18.0 - 104.3 16.1 - 152.7
CKD Stage
 Stage 1 (eGFR 90+) 67 (2.2 %) 15 (2.5 %) 8 (1.6 %) 90 (2.2 %)
 Stage 2 (eGFR 60 - 89) 662 (22.1 %) 173 (28.3 %) 117 (23.5 %) 952 (23.2 %)
 Stage 3 (eGFR 30 - 59) 2064 (68.8 %) 397 (64.9 %) 335 (67.3 %) 2796 (68.0 %)
 Stage 4 (eGFR 15 - 29) 207 (6.9 %) 27 (4.4 %) 38 (7.6 %) 272 (6.6 %)
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Table 3
Power comparisons for completed clinical trials, and FAVORIT










NORVIT7 0.182 0.16 0.33 0.54
Hope-29 0.198 0.46 0.81 1.00
VISP11 0.171 0.27 0.55 0.81
SWISS Heart10 0.228 0.08 0.14 0.23
Wrone et al12 0.417 0.10 0.18 0.31
CHAOS II*6 0.100 0.10 0.18 0.30
ASFAST13 0.541 0.13 0.26 0.43
HOST**8 0.238 0.24 0.48 0.73
WAFACS*5 0.148 0.33 0.65 0.89
FAVORIT***20 0.186 0.32 0.63 0.88
Note: Event rates in the control group are the observed event rates for all studies except FAVORIT. For FAVORIT, the event rate is the projected event
rate from the protocol.
*
Event rates not given by treatment group; total event rate divided by 2
**
Event rates for fatal and non-fatal MI, fatal and non fatal stroke, and amputation, pooled
***
Not observed data; based on design
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